Pharmacogenomic testing offers enormous potential to manage mental disorders like depression. But many psychoanalysts aren't aware of its value and biotechnical power. This article explains how this form of personalized medicine can be used to aid in the treatment of patients with depression. With over 20 medications approved by the FDA to treat depression, and many others recommended for off-label use, treatment failure with antidepressants commonly occurs in clinical practice. Inviting genetic...

Alzheimer's disease (AD) is the most common neurodegenerative dementia, and over 5.7 million Americans are living with a diagnosis of AD. AD is the 6th leading cause of death in the US and the costs associated with care for the disease are estimated to be $277 billion. As the population ages the prevalence of AD is expected to grow dramatically, with estimates reaching up to 14 million by 2050 Mexican Americans are one of the fastest aging populations in the US, and are at increased risk of deve...

There is little empirical research on patients at the severe level of personality organization who generally need more clarifications of roles, tasks, boundaries, and supportive interventions, and often create increased problems with countertransference. The purpose of this study was to investigate the relationship between clinicians' ratings of their new patients' level of personality organization traits (i.e.: Defensiveness, identity integration, object relations, and reality testing) and degr...